Search

The aim of this in vivo study was to evaluate the feasibility of ^{99m} Tc-labeled cartilage link protein (CLP) probe for the single-photon emission computed tomography (SPECT) of lung cancer. Xenograft mouse model were established from a luciferase expressing cell line derived from a human lung cancer. Bioluminescence imaging (BLI) was carried out prior to ^{99m} Tc-CLP and ^{99m} Tc-methoxyisobutyl isonitrile (MIBI) SPECT scans. The image quality of ^{99m} Tc-CLP scan was validated with BLI and compared with well established ^{99m} Tc-MIBI scan. Results of multimodal imaging analyses suggested that ^{99m} Tc-CLP was a sensitive and reliable SPECT agent for lung cancer imaging.

OBJECTIVES: To study the effect of γ irradiation on β-adrenergic receptors of the lung. MATERIALS AND METHODS: Healthy Sprague-Dawley rats were used as an animal model. Cell membrane proteins of lung tissue were harvested after the whole lung received 20 Gy of 60Co γ irradiation. 125I-labeled iodopindolol (125I-IPIN) was used as a ligand of β-adrenergic receptors. The numbers of the β-adrenergic receptors were determined by radioligand-receptor binding assay (RBA). Data were compared with irreversible blockage using antagonist bromoacetylalprenololmenthan (BAAM). RESULTS: The post-radiation RBA assay showed that the number of β-adrenergic receptors in lung tissue decreased at a steady rate. It decreased to 48% of the normal level at the 15th day after irradiation. At 40 days after radiation the level of β-adrenergic receptors started to increase at a steady rate and reached to the normal level around 70 days after radiation. There were significant differences in receptor synthesis, degradation and regeneration rates between irradiation group and BAMM group. CONCLUSIONS: The whole lung irradiation could severely affect the levels of β-adrenergic receptors. The potential clinical implications of radiation-induced changes of β-adrenergic receptors warrant further investigation.

The aim of this in vivo study was to evaluate the feasibility offormula^{99m}/formulaTc-labeled cartilage link protein (CLP) probe for the single-photon emission computed tomography (SPECT) of lung cancer. Xenograft mouse model were established from a luciferase expressing cell line derived from a human lung cancer. Bioluminescence imaging (BLI) was carried out prior toformula^{99m}/formulaTc-CLP andformula^{99m}/formulaTc-methoxyisobutyl isonitrile (MIBI) SPECT scans. The image quality offormula^{99m}/formulaTc-CLP scan was validated with BLI and compared with well establishedformula^{99m}/formulaTc-MIBI scan. Results of multimodal imaging analyses suggested thatformula^{99m}/formulaTc-CLP was a sensitive and reliable SPECT agent for lung cancer imaging.

To investigate the feasibility of using cartilage link protein of hyaluronic acid (HA-CLP) for defining the tumor boundary in a mouse model of lung carcinoma.Lung carcinoma was induced in KM mice by chemical carcinogenesis. HA-CLP separated from bovine cartilage and purified by affinity chromatography was labeled with (125)I for autoradiography. Immunohistochemical analysis and Western blotting were used to examine the efficiency of HA-CLP in defining the boundaries of the lung tumors.With autoradiography, the clearest image of lung cancer was obtained at 2 h. With immunohistochemical method, the tumor boundary was the most clearly displayed at 2 h when the strongest signals of HA-CLP was detected; Western blotting also showed the clearest bands of HA-CLP at 2 h.HA-CLP has the immunogenicity of HABP, and can efficiently indicate lung tumor boundary in autoradiography and immunohistochemistry.

Photodynamic therapy (PDT) has been used for the treatment of nonmalignant and malignant diseases from head to toe. Over the last decade its clinical application has gained increasing acceptance around the world. Pre-clinical studies demonstrate that, in addition to the direct local cytotoxicity and vascular effects, PDT can induce various host immune responses. Recent clinical data also show that improved clinical outcomes are obtained through the combination of PDT and immunomodulation. This review will summarize and discuss recent progress in developing innovative regimen of PDT combined with immunomodulation for the treatment of both nonmalignant and malignant diseases.

Photodynamic therapy (PDT) has been used for the treatment of non-malignant and malignant diseases from head to toe. Over the last decade its clinical application has gained increasing acceptance around the world. Pre-clinical studies demonstrate that, in addition to the direct local cytotoxicity and vascular effects, PDT can induce various host immune responses. Recent clinical data also show that improved clinical outcomes are obtained through the combination of PDT and immunomodulation. This review will summarize and discuss recent progress in developing innovative regimen of PDT combined with immunomodulation for the treatment of both non-malignant and malignant diseases.